Fitzsimon_menu

Innovation is happening. Right here.

Fitzsimons Innovation Community is a sprawling campus of leading-edge laboratory workspace where innovative health and life sciences companies of all sizes take their research to the next level to cure diseases, save lives, and improve care.

Smart, inclusive, forward-thinking, and highly educated people lead life sciences innovation in Colorado, the Hub for Health Impact. Together, we welcome life sciences organizations looking to call Colorado home and to collaborate with a robust community already in on the secret: the health and life sciences industry in Colorado is strong and making a global impact on the future of health.

 Move in, and build your vision here—today.

Community

The emphasis is on Community

We called it a community for a reason. From the board of directors to the newest company on campus, everyone at Fitzsimons Innovation Community knows that easy access to collaboration has direct results on success. From idea incubation to final-product manufacturing, your end-to-end innovation can come alive right here on our campus. All that Colorado sunshine is just a bonus.

Community

Cutting-edge discoveries in action

$72M

Capital Raised

Last year, Fitzsimons Innovation Community member companies attracted more than $72M in investments to support R&D, prepare for clinical trials, accelerate commercialization, retain or recruit talent, and expand to new markets.

50%

Companies Fundraising

Fitzsimons Innovation Community member companies are actively involved in fundraising to power their progress.

30%

Companies Launching New Products

Fitzsimons Innovation Community member companies are launching new products and solutions to market.

*Fitzsimons Innovation Community Member Growth Survey responses (January – December 2024)

A heritage of healthcare and innovation

Fitzsimons Innovation Community stands on the grounds that once held the Fitzsimons Army Hospital, where soldiers returning from World War I were treated. The Colorado high altitude has always been a destination for advancements in lung treatment, and 100 years ago, soldiers sought cures for tuberculosis and mustard gas exposure right here.

After the Army decommissioned the hospital in the 1990s, ideas for the current University of Colorado Anschutz Medical Campus and Fitzsimons Innovation Community began to percolate. That rich history of discovery, care, and research continues to inspire our vision a century later.

Our team is on your team

You know best when it comes to your projects, and we know how to keep you up and running with first-class scientific facilities management and community engagement. Our priority is to help you thrive on this campus and we have the proven tools and expertise to make that happen.

Bruce Schmidt

Chief Engineer

Don Larson

Facilities engineer

Juliena Carlson

Property Administrator

Julie Ehler

Controller

Kelly Brough

President & CEO

Kenneth Ho

Chief Operating Officer

Laurie Troge

Chief of Staff

Lyle Artz

Site manager

Sue Niblo

Senior property manager

"It’s amazing to me how many times the conversations between people at Fitzsimons seem to result in great things for the companies here. Startups are getting advice from larger companies about how to properly scale. They’re really helping each other, and it’s exciting to experience."

Robin Shandas

CEO, EnteroTrack

"Fitzsimons Innovation Community is an excellent place to build a life science business at any stage of development."

Roland Marcus

COO, Peak Diagnostic Partners

Community

Fitzsimons Innovation Community News

Fitzsimons Innovation Community Members Receive OEDIT Early-Stage Capital and Retention Grants
News | Nov 20, 2025

Fitzsimons Innovation Community Members Receive OEDIT Early-Stage Capital and Retention Grants

The Global Business Development division of the Colorado Office of Economic Development and International Trade (OEDIT) announced that 17 Colorado companies and eight researchers have been awarded Proof of Concept and Early-Stage Capital and Retention grants through OEDIT’s Advanced Industries Accelerator Program. Congratulations to the Fitzsimons Innovation Community Early-Stage Capital and Retention Grant Recipients: Onconaut Therapeutics, Inc., Vega Surgical, Inc., and Vona Oncology LLC.

UCHealth is First in Colorado to Offer Mammogram Technology that Better Detects Hidden Breast Cancer
News | Nov 18, 2025

UCHealth is First in Colorado to Offer Mammogram Technology that Better Detects Hidden Breast Cancer

UCHealth said it's the first in Colorado to offer a kind of mammogram that could be a game changer when it comes to detecting breast cancer. Dr. Elizabeth Vorhis, a breast radiologist said she uses an IV contrast during a mammogram. It's the same kind of process if you go to the emergency room and get a stomach or chest CT scan.

Fitzsimons Innovation Community Members Honored at CBSA 22nd Annual Awards Celebration
News | Nov 14, 2025

Fitzsimons Innovation Community Members Honored at CBSA 22nd Annual Awards Celebration

Colorado BioScience Association (CBSA) announced the winners of its 22nd Annual Awards Celebration, recognizing the people and organizations advancing Colorado’s position as a leading hub for health innovation. The awards spotlight leaders whose work accelerates breakthrough discoveries and delivers impact for patients in Colorado and around the world. Dr. Katherine Goodman, Associate Professor at the University of Colorado Denver | Anschutz, received the Educator of the Year Award for her outstanding contributions to shaping Colorado’s future life sciences workforce. EnteroTrack and RheumaGen were honored as Rising Star of the Year finalists.

UCHealth Patient Pioneers Innovative Adaptive Brain Stimulation Device for Parkinson’s
News | Nov 06, 2025

UCHealth Patient Pioneers Innovative Adaptive Brain Stimulation Device for Parkinson’s

Earlier this year, Kate Goes became the first patient in North America to use FDA-approved adaptive deep brain stimulation (DBS) technology for Parkinson’s. UCHealth Ph.D. clinical neuropsychologist John Thompson helped make the pathbreaking innovation possible.

CU Anschutz Researchers Make Drug Dosing Safer for Babies
News | Nov 01, 2025

CU Anschutz Researchers Make Drug Dosing Safer for Babies

Earlier this year, Kate Goes became the first patient in North America to use FDA-approved adaptive deep brain stimulation (DBS) technology for Parkinson’s. UCHealth Ph.D. clinical neuropsychologist John Thompson helped make the pathbreaking innovation possible.

Cystic Fibrosis Treatment Shows Long-Term Reduction in Inflammation
News | Oct 30, 2025

Cystic Fibrosis Treatment Shows Long-Term Reduction in Inflammation

Earlier this year, Kate Goes became the first patient in North America to use FDA-approved adaptive deep brain stimulation (DBS) technology for Parkinson’s. UCHealth Ph.D. clinical neuropsychologist John Thompson helped make the pathbreaking innovation possible.

CU System Climbs to $12.2 Billion in Economic Impact Across State
News | Oct 30, 2025

CU System Climbs to $12.2 Billion in Economic Impact Across State

The University of Colorado system generated $12.2 billion in economic impact across Colorado last year, highlighting CU’s growing role in the state’s economy through education, research, innovation and health care, according to a new economic study. This is growth of more than half a billion dollars over 2024.

What Researchers All Know: Location Matters
News | Oct 15, 2025

What Researchers All Know: Location Matters

Colorado Real Estate Journal's latest Health Care and Life Sciences Quarterly features an article from Dr. Terry Fry, Executive Director of the Gates Institute at University of Colorado Anschutz, about how the proximity between academia, biomanufacturing, and industry collaboration at Fitzsimons accelerates the development of life-changing cell and gene therapies.

Verily Launches Landmark Partnership with CU Anschutz and UCHealth
News | Oct 14, 2025

Verily Launches Landmark Partnership with CU Anschutz and UCHealth

Precision health and medicine giant Verily will be partnering with CU Anschutz and UCHealth to create an AI enabled ecosystem entailing research ready biomedical pipelines and datasets. In addition, the partnership is aiming to build curated AI models across a variety of specific therapeutic and drug areas, such as oncology, musculoskeletal and transplant medicine, to name a few. All of this work will be done using CU Anschutz’s vast research datasets via Verily Workbench, one of the company’s flagship products.

RheumaGen and SiVEC Biotechnologies Announce CGT Partnership and In Vivo Program to Cure Common Autoimmune Diseases
News | Oct 10, 2025

RheumaGen and SiVEC Biotechnologies Announce CGT Partnership and In Vivo Program to Cure Common Autoimmune Diseases

RheumaGen, Inc. and SiVEC Biotechnologies, Inc. today announced a licensing and joint development agreement for a breakthrough class of gene-editing therapies designed to cure autoimmune diseases. The partnership will utilize SiVEC's BactPac™ drug delivery platform to streamline manufacturing and increase scalability of RheumaGen's new class of human leukocyte antigen (HLA) gene-editing therapies for common autoimmune diseases; importantly, the partnership also establishes an in vivo program that will be co-developed by the companies.

Want to stay on top of what’s happening on campus?

Sign up for regular updates from Fitzsimons Innovation Community.